AstraZeneca hails positive findings in breast cancer drug trial

by | Dec 8, 2022

AstraZeneca said on Thursday that a phase III trial of its capivasertib drug in combination with Faslodex (fulvestrant) had demonstrated a “statistically significant and clinically meaningful” improvement in progression-free survival in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.
The results, which were versus placebo plus Faslodex, showed that capivasertib and Faslodex demonstrated a 40% reduction in the risk of disease progression or death.

Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, said: “Capivasertib brings important progress to an area with persistent treatment gaps as the first therapy of its kind shown to be effective in a Phase III trial in patients with advanced HR-positive, HER2-low or negative breast cancer.

“We believe these results which showed benefit in all-comers and biomarker positive populations can reshape HR-positive breast cancer treatment, and that capivasertib can become an important new option for patients.”

Related articles

Ceres Power warns on revenues, shares tank

Ceres Power warns on revenues, shares tank

(Sharecast News) - Ceres Power tanked on Friday after warning on full-year revenues, as it conceded it was unlikely to sign new deals in time for the revenue to be recognised in 2023. After the close of markets on Thursday, Ceres - which develops clean energy...

Latest Articles

Join our mailing list

Subscribe to our mailing list to receive regular updates!